文献速递细菌感染、耐药与抗菌药物

磷霉素联合美罗培南对肺炎克雷伯菌的体外药效学研究

The pharmacodynamics of fosfomycin in combination with meropenem against Klebsiella pneumoniae studied in an in vitro model of infection.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

采用体外药代动力学模型,研究磷霉素联合美罗培南对6株磷霉素MIC 8-1024 mg/L、美罗培南MIC 0.06->1024 mg/L的肺炎克雷伯菌的药效。联合美罗培南后,5/6株磷霉素抑菌所需fAUC/MIC降至<10,杀菌(2 log下降)所需<30,并抑制磷霉素耐药群体变化。

要点

  • 磷霉素单药对5/6株肺炎克雷伯菌24小时抑菌fAUC/MIC>500。
  • 联合美罗培南后5/6株抑菌fAUC/MIC<10,2 log杀菌<30。
  • 联合美罗培南抑制磷霉素耐药群体变化,美罗培南群体无变化。

核心结论

  • 加入美罗培南显著降低磷霉素达到抑菌和杀菌效应所需的fAUC/MIC暴露,并抑制磷霉素耐药的出现。

研究设计与样本

  • 体外药代动力学稀释模型,采用6株肺炎克雷伯菌,磷霉素MIC 8-1024 mg/L,美罗培南MIC 0.06->1024 mg/L。
  • 磷霉素暴露范围至fAUC/MIC 500,美罗培南对美罗培南MIC≥32 mg/L的菌株按2 g每8小时人用剂量相关暴露,对MIC<32 mg/L的菌株按半数抑菌fT>MIC暴露。
  • 主要终点为24小时药物暴露后细菌负荷相对初始接种量的对数变化,并计算药效fAUC/MIC比值;通过群体谱评估耐药出现风险。

主要发现

  • 磷霉素单药24小时抑菌fAUC/MIC在5/6株肺炎克雷伯菌中>500。
  • 美罗培南对美罗培南MIC≤64 mg/L的菌株抑菌fT>MIC为16.6%-77.9%。
  • 联合美罗培南后磷霉素fAUC/MIC均降低,5/6株抑菌fAUC/MIC<10,2 log下降fAUC/MIC<30。
  • 加入美罗培南抑制磷霉素群体谱变化,联合暴露下美罗培南群体谱无变化。

关键数值与推荐

  • 磷霉素单药24小时抑菌fAUC/MIC>500(5/6株)。
  • 联合美罗培南时磷霉素抑菌fAUC/MIC<10(5/6株),2 log杀菌fAUC/MIC<30(5/6株)。
  • 美罗培南抑菌fT>MIC为16.6%-77.9%(美罗培南MIC≤64 mg/L的菌株)。

局限性

  • 美罗培南MIC>1024 mg/L的菌株未检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intravenous fosfomycin is used in combination with other antimicrobials for the management of severe and/or multidrug resistant Gram-negative infection. We used an in vitro pharmacokinetic model to study the combination of fosfomycin plus meropenem. METHODS: Six Klebsiella pneumoniae fosfomycin MICs 8-1024 mg/L, meropenem MICs 0.06->1024 mg/L were employed. A dilutional pharmacokinetic model was used to generate fosfomycin exposure ranges up to a fAUC/MIC 500. Exposure-ranging experiments were repeated in the presence of meropenem at exposures associated with 2 g 8-hourly human dosing for strains with meropenem MICs ≥32 mg/L and at half the bacteriostatic fT > MIC for strains with MICs <32 mg/L. The log change in bacterial burden from the initial inoculum after 24 h drug exposure was taken as the primary endpoint and fAUC/MIC ratios for antibacterial effects were calculated. The risk of emergence of resistance was assessed by measurement of the population profiles. RESULTS: Fosfomycin fAUC/MIC for bacteriostatic effect at 24 h were >500 for 5/6 K. pneumoniae strains. Meropenem fT > MIC for static effect were 16.6%-77.9% for the strains with meropenem MIC ≤ 64 mg/L. Strains with MICs of >1024 mg/L were not tested. Fosfomycin fAUC/MICs in the presence of meropenem were all reduced and for 5/6 strains the fAUC/MIC for static effect was <10 and <30 for a 2 log drop. Addition of meropenem suppressed changes in fosfomycin population profiles. There were no changes in meropenem population profiles exposed to the combination. CONCLUSION: Addition of meropenem to fosfomycin had a dramatic impact on the fosfomycin fAUC/MIC exposures required for bacteriostatic and bactericidal effects and suppressed emergence of fosfomycin resistance.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. MacGowan AP, Griffin P, Attwood MLG, et al. The pharmacodynamics of fosfomycin in combination with meropenem against Klebsiella pneumoniae studied in an in vitro model of infection. J Antimicrob Chemother. 2025. PMID: 39887074. doi:10.1093/jac/dkaf020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。